A mutation site enriched shingled probe, kit, design method and application

By designing mutation site-enriched stacked tiles probes, efficient capture of EGFR gene mutation sites is achieved, which solves the problem of poor capture effect of conventional probes and improves the accuracy and efficiency of detection.

CN117802204BActive Publication Date: 2024-11-15国药(武汉)精准医疗科技有限公司 +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410006700.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-01-03
Publication Date
2024-11-15
Estimated Expiration
2044-01-03

AI Technical Summary

Technical Problem

The conventional stacked tiles design in the prior art targets clinically important but low-frequency mutation sites capture effects and detection rates are not ideal, especially in the detection of EGFR genes, which are difficult to accurately capture mutant DNA.

Method used

Design a mutation site-enriched stacked tiles probe, and achieve 2X coverage by placing multiple probes staggered, and design complementary sequences for mutation sites, increase the probe level to achieve 3X coverage, and improve difficult-to-capture sites capture efficiency.

Benefits of technology

It significantly improves the capture rate and detection rate of low mutation frequency sites, ensures that clinically meaningful mutation sites can reach 3X coverage, and significantly improves the accuracy and efficiency of detection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117802204B_ABST
    Figure CN117802204B_ABST
Patent Text Reader

Abstract

The present application provides a mutation site-enriched shingled probe, a kit, a design method and an application. The design method of the mutation site-enriched shingled probe includes the following steps: design multiple probes for the gene to be detected; stagger the multiple probes to achieve 2X coverage of all gene regions to be detected; for the mutation site, design the probe sequence as the complementary sequence of the mutation site; for the hard-to-capture site, add a layer of probe so that the hard-to-capture site reaches 3X coverage. A mutation site-enriched shingled probe of the present application can achieve 3X coverage of clinically significant mutation sites, improving the enrichment rate and detection rate of sites with low mutation frequency in the sample. A mutation site-enriched shingled probe kit of the present application is used in the detection of EGFR genes, which significantly improves the capture efficiency and detection rate of mutation sites while realizing EGFR gene detection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the field of gene detection technology, and more specifically, relates to a mutation site enriched shingled probe, a kit, a design method and an application. Background Art

[0002] In the second-generation sequencing gene detection of tumors, it is necessary to enrich the targeted gene region. There are two main ways to achieve targeted enrichment. One is to directly amplify the target region through multiplex PCR, and the other is to achieve hybrid capture of the pre-library through oligonucleotide probes. Due to the cross-amplification and uneven amplification efficiency of multiplex PCR, the applicable scenarios are limited. The hybridization enrichment method based on probes (Probe & Panel) is compatible with the detection of multiple variant types and is easy to optimize to obtain better sequencing uniformity, so it has been widely used. In response to general needs, many companies have provided catalog panels and hybridization capture solutions, such as whole exon and pan-cancer applications. It is more recommended to directly purchase commercial panels than to design them from scratch, because these panels are usually verified and optimized. However, when some experiments or tests need to target specific genes, fixed diseases or special signaling pathways, customized panel design and synthesis are required. Customized panel design needs to take into account the selection of target regions, probe positions and methods, all of which are directly related to the capture effect.

[0003] The EGFR G719S site frequently appears in colorectal cancer and lung cancer. The corresponding recommended drugs in clinical practice are cetuximab, erlotinib, and gefitinib. Among the rare EGFR mutations in NSCLC, the G719X mutation (including G719S, G719A, G719C, and G719D) is one of the more common mutations after the exon 20 insertion mutation, accounting for approximately 1.53% of all EGFR mutations in NSCLC, which is a relatively low proportion. It is particularly important to accurately detect this site and provide auxiliary diagnosis and treatment recommendations for clinical practice.

[0004] For the detection of EGFR gene mutation sites, there are generally three positions for probe placement: shingled, head-to-tail, and spaced. The shingled capture uniformity is better and is also the placement method commonly used by manufacturers. In general tumor samples, the mutation frequency of clinically significant sites is not 100%. Some mutation frequencies are as low as 1%, which means that one mutant DNA needs to be captured among 100 wild-type DNAs. If conventional shingled probes are used, they tend to capture wild-type DNA, that is, the capture effect and detection rate for clinically significant and difficult-to-capture mutation sites such as the EGFR gene are not ideal. Therefore, the enrichment effect of conventional shingled probes still needs to be improved. Summary of the invention

[0005] The purpose of the present application is to provide a mutation site enriched shingled probe, kit, design method and application to solve the technical problem that conventional shingled probes in the prior art have unsatisfactory capture effect and detection rate for clinically significant and difficult-to-capture mutation sites such as the EGFR gene.

[0006] To achieve the above objectives, the first aspect of the present application provides a method for designing mutation site-enriched shingled probes, comprising the following steps:

[0007] Design multiple probes targeting the genes to be detected;

[0008] The plurality of probes are placed in a staggered manner to achieve 2X coverage of all gene regions to be detected;

[0009] For the mutation site, the probe sequence is designed to be the complementary sequence of the mutation site;

[0010] For sites that are difficult to capture, an additional layer of probes is added to achieve 3X coverage of the sites that are difficult to capture.

[0011] In a second aspect of the present application, a mutation site-enriched shingled probe is provided, which is obtained using the design method described above.

[0012] The third aspect of the present application provides a kit, comprising the mutation site-enriched shingled probe described above.

[0013] The fourth aspect of the present application provides an application of a mutation site-enriched shingled probe in detecting the EGFR gene.

[0014] Furthermore, the sequences of the shingled probes used are shown in SEQ ID NOs: 1-56.

[0015] The fifth aspect of the present application provides a kit for use in detecting EGFR gene.

[0016] Furthermore, the sequences of the shingled probes used are shown in SEQ ID NOs: 1-56.

[0017] Furthermore, the detection process includes the following steps: preparation of DNA sample library, construction of DNA library, hybridization of detection probe with DNA library and detection based on next generation sequencing technology, bioinformatics analysis to identify mutations, interpretation of mutations and issuance of a report based on the interpretation results.

[0018] Compared with the prior art, this application has the following technical effects:

[0019] Conventional shingled probes tend to capture wild-type DNA, while the mutation site enriched shingled probes of the present application can effectively enrich mutant DNA, inhibit the binding of wild-type DNA, and improve the capture efficiency and detection rate of clinically significant tumor sites. A mutation site enriched shingled probe of the present application can achieve 3X coverage of clinically significant mutation sites, improving the enrichment rate (capture rate) and detection rate of sites with low mutation frequency in samples.

[0020] The present application discloses a mutation site-enriched shingled probe kit for use in detecting EGFR genes, which significantly improves mutation site capture efficiency and detection rate while achieving EGFR gene detection. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] In order to more clearly illustrate the technical solutions in the embodiments of the present application, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative labor.

[0022] Figure 1 A is a schematic diagram of the design of a conventional head-to-tail connected probe provided in Example 1 of the present application; Figure 1 B is a schematic diagram of the design of a conventional shingled probe provided in Example 1 of the present application; Figure 1 C is a schematic diagram of the design of the mutation site-enriched shingled probes of the present invention provided in Example 1 of the present application. DETAILED DESCRIPTION

[0023] In order to make the technical problems, technical solutions and beneficial effects to be solved by the present application more clearly understood, the present application is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present application and are not used to limit the present application.

[0024] The terms used in the embodiments of the present application are only for the purpose of describing specific embodiments, and are not intended to limit the present application. The singular forms "a", "said" and "the" used in the embodiments of the present application and the appended claims are also intended to include plural forms, unless the context clearly indicates other meanings.

[0025] The weight of the relevant components mentioned in the embodiment description of the present application can not only refer to the specific content of each component, but also represent the proportional relationship between the weights of the components. Therefore, as long as the content of the relevant components is proportionally enlarged or reduced according to the embodiment description of the present application, it is within the scope disclosed in the embodiment description of the present application. Specifically, the mass described in the embodiment description of the present application can be a mass unit known in the chemical industry such as μg, mg, g, kg, etc.

[0026] Example 1

[0027] Embodiment 1 of the present application provides a method for designing mutation site-enriched shingled probes, comprising the following steps:

[0028] (1) Design multiple probes for the genes to be detected;

[0029] (2) Multiple probes are placed in an interlaced manner to achieve 2X coverage of all gene regions to be detected;

[0030] (3) Designing the probe sequence to be complementary to the mutation site;

[0031] (4) For sites that are difficult to capture, add a layer of probes to achieve 3X coverage of the sites that are difficult to capture.

[0032] Specifically, the EGFR G719S c.2155 site of the gene to be detected is used as an example. The wild-type site is a G base. If the conventional shingled probe design is used, the base of the site will be set to C, such as Figure 1 B, and conventional shingled probes are stacked up layer by layer, and in some areas, as shown in the dotted line range in the figure, the actual coverage is only 1X; while the mutation site enriched shingled probe design of the present invention, such as Figure 1 C. The probes are placed in an alternating manner to achieve 2X coverage of all areas. For mutation sites, the probe sequence is designed to be the complementary sequence T of the mutation site. For sites that are difficult to capture, a layer of probes is added to achieve 3X coverage of clinically significant sites. This can increase the enrichment rate (capture rate) and detection rate of sites with low mutation frequency in the sample.

[0033] The probe group obtained by conventional head-to-tail connected probe design is recorded as group A, the probe group obtained by conventional shingled probe design is recorded as group B, and the mutation site enriched shingled probe group obtained by the novel shingled design of the present invention is recorded as group C. The designs of the three probes are as follows: Figure 1 .

[0034] Example 2

[0035] Example 2 of the present application provides an application of a mutation site-enriched shingled probe in detecting the EGFR gene. The detection process mainly includes the following steps: preparing a DNA sample library, constructing a DNA library, hybridizing the detection probe with the DNA library and performing detection based on next-generation sequencing technology, identifying mutations through bioinformatics analysis, interpreting the mutations and issuing a report based on the interpretation results.

[0036] For the EGFR gene, probes including the sequences shown in SEQ ID NOs: 1 to 56 were designed.

[0037] The specific detection process includes the following steps:

[0038] 1. Sample preparation

[0039] For standard samples, no extraction is required. Just take the required amount in the next step. For paraffin-embedded tissue samples, use QIAGEN's QIAamp DNA FFPE Tissue Kit. For blood samples, use the Novozymes DC112 manual extraction kit. Strictly follow the instructions. The extracted DNA needs to be quantitatively tested. The extracted DNA is used The total amount of extraction should be no less than 50ng when tested with dsDNAHS Assay Kit and supporting instruments.

[0040] 2. DNA library construction and hybridization capture

[0041] Conventional head-to-tail connected probes (Group A), conventional shingled probes (Group B) and mutation site enriched shingled probes of the present invention (Group C) were used for hybridization capture.

[0042] The specific process of DNA library construction is as follows:

[0043] 2.1 Genomic DNA fragmentation, end repair, and 3' end addition of "A"

[0044] 2.1.1 Place the reagents Fragment & ERA Enzyme Mix and Fragment & ERA Buffer on an ice box to melt, and configure the reaction system according to the following table:

[0045]

[0046] 2.1.2 Set the vortexer to Touch mode, oscillate 8 times, centrifuge at low speed for 3 seconds, and repeat the above steps once.

[0047] 2.1.3 Run the PCR program and set the PCR instrument parameters as follows. When the program runs to 4°C, take the PCR tube out of the ice box and place it in the PCR instrument to continue running the program: hot cover temperature 85°C, 4°C for 1 min, 37°C for 18 min (whole blood sample: 18 min, FFPE: 8 min), 65°C for 30 min, 4°C hold.

[0048] 2.1.4 After the program is completed, proceed to the next step of ligation reaction immediately.

[0049] 2.2 Connector connection

[0050] 2.2.1 In the PCR tubes for the above reaction, prepare the reaction system on an ice box according to the following table:

[0051]

[0052] 2.2.2 Use a pipette to mix (avoid violent shaking), and centrifuge briefly.

[0053] 2.2.3 Run the PCR program (close the hot cover) and set the PCR parameters as follows: close the hot cover, set the volume to 100ul; 22℃for 15min; 4℃for∞.

[0054] 2.3 Post-ligation purification

[0055] 2.3.1 Take out the Agencourt AMPure XP magnetic beads from the 4℃ refrigerator and bring them to room temperature. Vortex and mix well and set aside.

[0056] 2.3.2 Add 0.8 times the volume of magnetic beads (88 μL) to the ligation product of Step 2, vortex and mix or pipette and mix, and let stand at room temperature for 5 minutes.

[0057] 2.3.3 Briefly centrifuge and place the PCR tube on a magnetic rack for 3 minutes to allow the solution to clarify.

[0058] 2.3.4 Keep the PCR tube on the magnetic rack, remove the supernatant, add 200 μL 80% ethanol solution into the PCR tube, and let it stand for 30 seconds.

[0059] 2.3.5 Keep the PCR tube on the magnetic rack, remove the supernatant, add 200 μL 80% ethanol solution to the PCR tube again, let it stand for 30 seconds, and then completely remove the supernatant (a 10 μL pipette can be used to remove the residual ethanol solution at the bottom).

[0060] 2.3.6 Let stand at room temperature for 3-5 minutes to allow the residual ethanol to evaporate completely.

[0061] 2.3.7 Add 22 μL of Nuclease-free Water, remove the PCR tube from the magnetic rack, vortex or pipette to mix, and let stand at room temperature for 2 minutes.

[0062] 2.3.8 Briefly centrifuge and place the PCR tube on a magnetic rack for 2 minutes to allow the solution to clarify.

[0063] 2.3.9 Use a pipette to aspirate 20 μL of supernatant and transfer it to a new PCR tube (placed on an ice box), mark it, and prepare for the next reaction.

[0064] 2.4 Pre-PCR reaction

[0065] 2.4.1 Take out PCR MasterMix and UDIPrimer from the -20℃ refrigerator, place them on an ice box to dissolve, mix well and place on ice for later use.

[0066] 2.4.2 Prepare the PCR reaction system on an ice box according to the corresponding system:

[0067]

[0068] 2.4.3 Vortex or pipette to mix, then centrifuge briefly.

[0069] 2.4.4 Place the sample on the PCR instrument and start the PCR program as follows: hot cover temperature 105℃, volume setting 50ul; 98℃ for 2min; 98℃ for 20s, 60℃ for 30s, 72℃ for 30s, 6cycles; 72℃ for 1min; 4℃ hold.

[0070] 2.5 Purification after PCR amplification

[0071] 2.5.1 Take out the Agencourt AMPure XP magnetic beads from the 4℃ refrigerator and bring them to room temperature. Vortex and mix well and set aside.

[0072] 2.5.2 Add 1 volume of magnetic beads (50 μL) to the above PCR product, vortex or pipette to mix, and let stand at room temperature for 5 minutes.

[0073] 2.5.3 Briefly centrifuge and place the PCR tube on a magnetic rack for 3 minutes to allow the solution to clarify.

[0074] 2.5.4 Keep the PCR tube on the magnetic rack, remove the supernatant, add 200 μL 80% ethanol solution into the PCR tube, and let it stand for 30 seconds.

[0075] 2.5.5 Keep the PCR tube on the magnetic rack, remove the supernatant, add 200 μL 80% ethanol solution to the PCR tube again, let it stand for 30 seconds, and then completely remove the supernatant (a 10 μL pipette can be used to remove the residual ethanol solution at the bottom).

[0076] 2.5.6 Let stand at room temperature for 3-5 minutes to allow the residual ethanol to evaporate completely.

[0077] 2.5.7 Add 30 μL of Nuclease-free Water, remove the PCR tube from the magnetic rack, vortex or pipette to mix, and let stand at room temperature for 2 minutes.

[0078] 2.5.8 Centrifuge briefly and place the PCR tube on a magnetic rack for 2 minutes to allow the solution to clarify.

[0079] 2.5.9 Use a pipette to aspirate 28 μL of supernatant, transfer it to a new PCR tube (placed on an ice box), and mark it.

[0080] 2.6Qseq100 detection library fragment distribution

[0081] 2.6.1 According to the instrument operation procedure, the main peak of the library fragment size is detected to be qualified if it is between 270-350bp.

[0082] 2.7 Library pooling, blocking and concentration

[0083] 2.7.1 Take out Un-Blocker and Human Cot-1 DNA from -20℃ refrigerator in advance, put them on ice box to thaw, mix well and place on ice or 4℃ for later use.

[0084] 2.7.2 Take 1000ng of library and add it to the PCR tube and mark it. When multiple libraries are mixed for hybridization, add 500ng to each library.

[0085] 2.7.3 Add the hybridization reaction system to the PCR tube according to the following table:

[0086]

[0087] 2.7.4 Vortex to mix the reaction system thoroughly, centrifuge briefly, and collect all components at the bottom of the tube.

[0088] 2.7.5 Place the PCR tube (8-tube strip) in a vacuum rotary evaporator, rotate at 55-60°C in vacuum, 1500 rpm, and evaporate the reaction solution to dryness.

[0089] 2.8 Library hybridization capture

[0090] 2.8.1 Remove HYB-Buffer, Enhancer, and Panel Probe from -20°C or 4°C; vortex and mix HYB-Buffer.

[0091] 2.8.2 Start PCR program Hybrid 2 in advance.

[0092] 2.8.3 Add the following reagents to the above evaporated PCR tubes (8 strip tubes):

[0093]

[0094] 2.8.4 Mix well by vortexing, leave at room temperature for 5-10 min, vortex again and centrifuge briefly.

[0095] 2.8.5 Perform cycle incubation on a PCR instrument with the following program (Hybrid 1): hot lid temperature 105°C, volume setting 20 μL; 9°C for 5 min.

[0096] 2.8.6 Vortex to mix and centrifuge briefly.

[0097] 2.8.7 Immediately place in PCR instrument for overnight hybridization at 65℃ (Hybrid 2): heat cover temperature 75℃, volume setting 20μL; 65℃ hold.

[0098] 2.9 Preparation of eluent

[0099] 2.9.1 Prepare sufficient elution buffer according to the number of N hybridization reactions:

[0100]

[0101] 2.9.2 Place the following reagents in a PCR instrument or metal bath at 65°C for at least 15 minutes.

[0102] SW: Preheat SW in a 65°C metal bath; or add 150 μL to each PCR tube for preheating.

[0103] W1: Take an equal amount of hybridization reaction, place in an EP tube and heat in a metal bath, or add 120 μL to each PCR tube and preheat.

[0104] 2.9.3 Place the following reagents at room temperature:

[0105] WⅠ: the above configuration, 150 μL / rxns, placed at room temperature;

[0106] WⅡ: the above configuration, 150 μL / rxns, placed at room temperature;

[0107] WⅢ: The above configuration, 150μL / rxns, placed at room temperature.

[0108] 2.10 Preparation of streptavidin magnetic beads

[0109] 2.10.1 Add N*50μL ProbeCap SA Beads according to N hybridization reactions and transfer to PCR tubes or EP tubes.

[0110] 2.10.2 Place the PCR tube or EP tube containing magnetic beads in the previous step on the magnetic rack and wait for the solution to separate from the magnetic beads.

[0111] 2.10.3 Discard the supernatant and keep the magnetic beads.

[0112] 2.10.4 Add 90*N μL 1X BWB for N hybridization reactions and vortex for 10 seconds.

[0113] 2.10.5 Place the PCR tube or EP tube containing magnetic beads in the previous step on the magnetic rack and wait for the solution to separate from the magnetic beads.

[0114] 2.10.6 Discard the supernatant and keep the magnetic beads.

[0115] 2.10.7 Repeat steps 2.10.4-2.10.6 once, washing the magnetic beads twice in total.

[0116] 2.10.8 Add 50*N μL of 1X BWB according to N hybridization reactions, vortex and mix thoroughly for later use.

[0117] 2.10.9 Aliquot 50 μL of the magnetic bead mixture into new PCR tubes (8-tube strips) for each hybridization reaction.

[0118] 2.11 Binding of library to streptavidin magnetic beads

[0119] 2.11.1 Place the PCR tubes (8-tube strips) from the previous step on the magnetic rack, wait for the solution to separate from the magnetic beads, discard the supernatant and keep the magnetic beads; proceed to the next step immediately to avoid excessive exposure of the magnetic beads to the air.

[0120] 2.11.2 Place the PCR tubes (8-tube strips) containing magnetic beads in the previous step into a 65°C PCR instrument.

[0121] 2.11.3 Transfer all 16 μL of the overnight hybridization reaction solution in the above step to the PCR tube (8-tube strip) containing SA magnetic beads, and immediately vortex to mix.

[0122] 2.11.4 Continue the reaction at 65°C in a hybridization PCR instrument (Hybrid 2) for 30-45 min.

[0123] 2.11.5 Take out and shake for 5 seconds every 10-12 minutes, then immediately put it into the PCR instrument for reaction until the total reaction time is met.

[0124] 2.1265℃ heat elution to remove unbound DNA

[0125] 2.12.1 Add 120 μL of 1X WI wash solution preheated at 65℃ to the PCR tube (8-tube strip) where the reaction was completed in the previous step, and quickly vortex to mix or quickly pipette to mix.

[0126] 2.12.2 Incubate in 65℃ PCR machine for 10-20 seconds, quickly return to the magnetic rack, and discard the supernatant as soon as possible.

[0127] 2.12.3 Add 150 μL of SW preheated at 65°C to the PCR tubes (8-tube strips) in the previous step and vortex to mix.

[0128] 2.12.4 Place the PCR tubes (8-tube strips) on the PCR instrument and incubate at 65°C for 5 minutes.

[0129] 2.12.5 Place the PCR tubes (8-tube strips) on the magnetic rack, wait for the solution to separate from the magnetic beads, and quickly discard the supernatant.

[0130] 2.12.6 Repeat steps 2.12.3-2.12.5 once, washing the magnetic beads twice in total.

[0131] 2.13 Elution at room temperature

[0132] 2.13.1 Add 140 μL of room temperature 1X WI washing solution to the PCR tubes (8-tube strips) in the previous step.

[0133] 2.13.2 Vortex for 30 seconds each time, 4 times in interval, and oscillate for a total of 2 minutes to fully suspend the magnetic beads.

[0134] 2.13.3 Place the PCR tubes (8-tube strips) on a magnetic rack, wait for the solution to separate from the magnetic beads, and discard the supernatant.

[0135] 2.13.4 Add 140 μL of room temperature 1X WⅡ washing solution to the PCR tubes (8-tube strips) in the previous step.

[0136] 2.13.5 Vortex for 30 seconds each time, take two times in between, and oscillate for a total of 1 minute to fully suspend the magnetic beads.

[0137] 2.13.6 Place the PCR tubes (8-tube strips) on a magnetic rack, wait for the solution to separate from the magnetic beads, and discard the supernatant.

[0138] 2.13.7 Add 140 μL of room temperature 1X WⅢ washing solution to the PCR tubes (8-tube strips) in the previous step.

[0139] 2.13.7 Vortex to mix well and transfer the mixture to a new PCR tube (8-tube strip).

[0140] 2.13.8 Place the PCR tubes (8-tube strips) on the magnetic rack, wait for the solution to separate from the magnetic beads, and discard the supernatant.

[0141] 2.13.9 Add 23 μL Nuclease-free water into the PCR tube (8-tube strip).

[0142] 2.14 Capture library PCR enrichment and library purification

[0143] 2.14.1 After capture, the DNA library needs to be amplified by PCR. Prepare the reaction system according to the following table:

[0144]

[0145] 2.14.2 Briefly vortex and centrifuge.

[0146] 2.14.3 Run the PCR instrument program (Post PCR): hot cover temperature 105℃; 98℃for45s; 98℃for15s, 57℃for30s, 72℃for30s (this step 12*cycles); 72℃for1min; 4℃hold.

[0147] 2.14.4 After PCR, add 50 μL of Agencourt AMPure XP magnetic beads to the sample, vortex or pipette to mix, and let stand at room temperature for 5 minutes.

[0148] 2.14.5 Briefly centrifuge and place the PCR tube on a magnetic rack for 3 minutes to allow the solution to clarify.

[0149] 2.14.6 Keep the PCR tube on the magnetic rack, remove the supernatant, add 200 μL 80% ethanol solution into the PCR tube, and let it stand for 30 seconds.

[0150] 2.14.7 Keep the PCR tube on the magnetic rack, remove the supernatant, add 200 μL of 80% ethanol solution to the PCR tube again, let it stand for 30 seconds, and then completely remove the supernatant (a 10 μL pipette can be used to remove the residual ethanol solution at the bottom).

[0151] 2.14.9 Let stand at room temperature for 3-5 minutes to allow the residual ethanol to evaporate completely.

[0152] 2.14.9 Add 25 μL of Nuclease-free water, remove the PCR tube from the magnetic rack, shake or pipette to mix 10 times, and let stand at room temperature for 2 minutes.

[0153] 2.14.10 Centrifuge briefly and place the PCR tube on a magnetic rack for 2 minutes to allow the solution to clarify.

[0154] 2.14.11 Use a pipette to transfer 23 μL of supernatant to a 1.5 mL centrifuge tube and mark the sample information.

[0155] 2.14.12 Take 1 μL of library and use Qubit dsDNA HS Assay Kit for quantification. Record the library concentration. The library concentration is qualified if it is 1-20 ng / μL.

[0156] 2.14.13 Take 1 μL of sample and use Qsep100 to measure the fragment length according to step 2.6. The main peak length of the library is between 270bp and 500bp, which is qualified.

[0157] 2.14.14 Perform library quality inspection and sequence the library after passing the quality inspection.

[0158] 3. Perform bioinformatics analysis on the sequencing results to obtain the mutation results of the test samples

[0159] The sequencing was performed using an Illumina Novasek 6000 sequencer. After sequencing, the software generated a FASTQ file containing the sequence and quality score of each sample. The FASTQ file was then aligned to the reference genome to generate a BAM file to process variant calling of different types of changes (SNV, small insertions or deletions, amplifications, translocations, and MSI).

[0160] Comparing the three data results of the test, as shown in Table 1, the data quality control of the three probe groups shows that the capture efficiency (TargetRate) of the probe of the present invention can reach 90.95%, while the other two can only reach a capture efficiency of nearly 80%. The coverage (uniformity) greater than 30X is also the best effect of the present invention.

[0161] Table 1

[0162]

[0163] Table 2-4 compares the detection performance of the three groups of probes for standard sites. It can be seen that in terms of site detection, the probes of the present invention can detect all of them, but the conventional shingled probes missed 2 low-frequency mutations, and the conventional head-to-tail connected probes missed 3. Among them, the common clinically significant site EGFR G719S was not detected. However, the probes of the present invention can accurately detect the EGFR G719S site and the value is the same as the reference value.

[0164] Table 2

[0165]

[0166] Table 3

[0167]

[0168] Table 4

[0169]

[0170] Clinical samples were used for extraction, library construction, sequencing, and analysis according to the steps in this embodiment. It can be seen that although the capture rate in clinical samples is lower than that in the standard, the probe of the present invention still performs best (Table 5), and in site detection, the mutation frequency is closer to the true value (Tables 6-8).

[0171] Table 5 Clinical sample quality control results

[0172]

[0173] Table 6 Clinical sample detection results

[0174]

[0175] Table 7 Clinical sample detection results

[0176]

[0177] Table 8 Clinical sample detection results

[0178]

[0179] The above embodiments only express several implementation methods of the present application, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the present application. It should be pointed out that, for a person of ordinary skill in the art, several modifications and improvements can be made without departing from the concept of the present application, and these all belong to the protection scope of the present application. Therefore, the protection scope of the present application shall be subject to the attached claims.

Claims

1. A mutation site enriched shingled probe set, characterized in that: The sequences of the shingled probe set are shown in SEQ ID NOs: 1 to 56.

2. A kit, characterized in that: It includes a mutation site-enriched shingled probe set as described in claim 1.

3. Use of a mutation site-enriched shingled probe set as described in claim 1 in the preparation of a kit for detecting EGFR gene.